We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 28, 2016

AUY922 Plus Trastuzumab Is Well Tolerated and Active in HER2-Positive Metastatic Breast Cancer

Oncotarget

 

Additional Info

Disclosure statements are available on the authors' profiles:

Oncotarget
Phase 1B/2 Study of the HSP90 Inhibitor AUY922 Plus Trastuzumab in Metastatic HER2-Positive Breast Cancer Patients who Have Progressed on Trastuzumab-Based Regimen
Oncotarget 2016 Jun 21;7(25)37680-37692, A Kong, D Rea, S Ahmed, JT Beck, R López López, L Biganzoli, AC Armstrong, M Aglietta, E Alba, M Campone, SF Hsu Schmitz, C Lefebvre, M Akimov, SC Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading